Multivariablea HR (95% CI) – Stage I | Multivariablea HR (95% CI) – Stage II/III | |
---|---|---|
Tumor type | ||
GCTs | Ref. | Ref. |
SCSTs | 1.06 (0.60–1.86) | 3.28 (1.88–5.73)*** |
Age (per 5-year increase) | 1.23 (1.20–1.26)*** | 1.13 (1.10–1.16)*** |
Race/ethnicity | ||
Non-Hispanic White | Ref. | Ref. |
Non-Hispanic Black | 1.18 (0.80–1.72) | 1.13 (0.81–1.56) |
Hispanic/other | 1.14 (0.95–1.38) | 1.12 (0.94–1.32) |
Insurance | ||
Private insurance | Ref. | Ref. |
Uninsured | 2.58 (2.08–3.21)*** | 2.07 (1.72–2.50)*** |
Medicaid/Medicare/other government insurance | 3.15 (2.64–3.75)*** | 2.31 (1.97–2.70)*** |
Income (per year) | ||
< $38,000 | Ref. | Ref. |
$38,000–$62,999 | 0.92 (0.74–1.15) | 0.96 (0.79–1.16) |
> $63,000 | 0.74 (0.56–0.98)* | 0.77 (0.61–1.02) |
Percent in ZIP code without a high school diploma | ||
> 21% | Ref. | Ref. |
7–20.9% | 0.87 (0.70–1.07) | 0.80 (0.67–0.97)* |
< 7% | 0.80 (0.61–1.06) | 0.68 (0.52–0.88)** |
Residence | ||
Metropolitan | Ref. | Ref. |
Urban/rural | 1.18 (0.98–1.42) | 1.09 (0.91–1.29) |
Charlson-Deyo comorbidity score | ||
0 | Ref. | Ref. |
≥ 1 | 2.03 (1.64–2.51)*** | 2.03 (1.68–2.45)*** |